Table 4.
mRNA expression of genes related to the NF-κB signaling pathway
| Gene | NP-1 concentration | ||
|---|---|---|---|
|
| |||
| 0 μg/mL | 4 μg/mL | 8 μg/mL | |
| ICAM-1 | 1.03 ± 0.30 | 1.50 ± 0.25# | 1.67 ± 0.04# |
| IL-1α | 1.09 ± 0.50 | 1.22 ± 0.30 | 1.57 ± 0.15# |
| IL-6 | 1.02 ± 0.25 | 1.10 ± 0.07 | 1.34 ± 0.30# |
| p65 | 1.03 ± 0.28 | 1.19 ± 0.16# | 1.23 ± 0.14# |
| iNOS | 1.00 ± 0.11 | 1.18 ± 0.26# | 1.53 ± 0.31# |
| COX2 | 1.01 ± 0.17 | 1.26 ± 0.42# | 2.66 ± 0.49**,# |
| AKT | 1.20 ± 0.89 | 1.31 ± 0.17 | 1.21 ± 0.27 |
| JUN | 1.06 ± 0.43 | 1.54 ± 0.17# | 2.66 ± 0.38**,# |
| mTOR | 1.07 ± 0.43 | 1.03 ± 0.80 | 1.29 ± 0.87# |
*Treatment with 4 or 8 μg/mL NP-1 for 36 h vs. intervention with 0 μg/mL NP-1 for 36 h. SPSS v20.0 software was used for statistical analysis. Comparisons between two groups were made with independent-sample t-tests or nonparametric tests.
**
P < 0.01.
#
indicates the factor that changed over 15% in the 4 μg/mL NP-1-treated and 8 μg/mL NP-1-treated groups compared with the 0 μg/mL NP-1-treated group.